CIBERONC
CIBERONC is a publicly funded Spanish biomedical research consortium coordinating cancer research across member institutions in seven regions via four working modules — Liquid Biopsy, Experimental Models, Immuno-Oncology, and Bioinformatics — and collaborative projects such as PANIPAC, METASTARG, and CloneSight.
- Company typePrivate
- Founded2007
- HeadquartersMadrid, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CIBERONC does
CIBERONC (Centro de Investigación Biomédica en Red Cáncer) is a publicly funded Spanish biomedical research consortium and a thematic area of the CIBER network, established in 2007 under the Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovación) and the Instituto de Salud Carlos III (ISCIII). Headquartered in Madrid (Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0) and operating with 22 employees, the consortium coordinates cancer research across member institutions in Madrid, Barcelona, Valencia, Salamanca, Santiago de Compostela, Navarra, and Asturias, serving cancer research groups, clinical researchers at hospitals and universities, and early-career researchers through training and mobility programs.
Its core offerings are organized into four working modules — Liquid Biopsy (circulating biomarkers: ctDNA, cfDNA, exosomes, CTCs), Experimental Models (PDO, 3D cultures, PDX, Hu-PDX, xenograft, GEMM), Immuno-Oncology (immunotherapy response prediction, nanotherapy), and Bioinformatics (cloud services on Microsoft Azure with virtual machines for data storage, sharing, and analysis) — plus the CANCERTOOL gene-expression visualization tool and the SpadaHC technology platform. Active programs cover digestive tract tumors, breast/gynecological cancers, respiratory tract tumors, hematological tumors, precision therapies, and molecular mechanisms, with collaborative projects including PANIPAC (photoactivatable nanoparticles for pancreatic cancer), METASTARG (anti-metastasis nanomedicine), and CloneSight (a minimal-residual-disease test for early breast cancer developed with Instituto Valenciano de Oncología).
The organization has no commercial revenue model; its budget is sourced from public research grants, cooperative project calls, and institutional support. Distribution occurs through collaborative research networks and member institutions rather than commercial channels, with engagement supported by its website (ciberonc.es), Twitter (@CIBERONC), and events such as the Liquid Biopsy Workshop, the Young Researchers Meeting, and participation in international conferences (EACR, ISLB, ASEICA, Gordon Research Conferences). Leadership transitioned in 2025 with Gema Moreno Bueno named Scientific Director, and the consortium maintains GDPR compliance with an appointed Data Protection Delegate.
CIBERONC firmographics
Firmographics- Name
- CIBERONC
- Legal name
- CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED M.P.
- Website
- https://ciberonc.es
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CIBERONC is a publicly funded Spanish biomedical research consortium coordinating cancer research across member institutions in seven regions via four working modules — Liquid Biopsy, Experimental Models, Immuno-Oncology, and Bioinformatics — and collaborative projects such as PANIPAC, METASTARG, and CloneSight.
- Ownership category
- akta.pro rank
Where CIBERONC is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
CIBERONC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations
Revenue model
- Public Research Funding: CIBERONC is a publicly funded research consortium supported by the Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovación) and ISCIII (Instituto de Salud Carlos III). Funding comes from competitive research grants, cooperative project calls, and institutional support rather than commercial revenue generation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CIBERONC product offering
Product offeringCore offering
CIBERONC (Centro de Investigación Biomédica en Red Cáncer) is a publicly funded Spanish biomedical research consortium that coordinates collaborative cancer research across member institutions. It operates four interconnected Working Modules — Liquid Biopsy, Experimental Models, Immuno-Oncology, and Bioinformatics — providing shared experimental models, standardized protocols, cloud-based bioinformatics infrastructure, and competitive project funding to advance cancer diagnosis, treatment, and precision oncology.
Product overview
CIBERONC is a biomedical research network focused on cancer (Centro de Investigación Biomédica en Red Cáncer), organized as a platform with four interconnected Working Modules: the Liquid Biopsy Working Module (specializing in circulating biomarkers and ctDNA analysis), the Experimental Models Working Module (providing in vitro and in vivo cancer models), the Immuno-Oncology Working Module (focused on immunotherapy research), and the Bioinformatics Working Module (offering cloud infrastructure and data analysis). Additional offerings include the SpadaHC technology platform, research projects like PANIPAC (nanoparticle therapy for pancreatic cancer) and METASTARG (anti-metastasis nanomedicine), diagnostic tools like CloneSight (MRD test for breast cancer), and the CANCERTOOL bioinformatics visualization tool.
Differentiator
Problem solved
Functional benefit
Brands
- Liquid Biopsy WM (Working Module): Working module focused on liquid biopsy and biomarker research for cancer management
- Experimental Models WM
- Immuno Oncology WM
- Bioinformatics WM
- CANCERTOOL
Products and services
- Liquid Biopsy Working Module A collaborative research module focused on advancing the application of circulating biomarkers in the liquid biopsy field to improve cancer management, including ctDNA, exosomes, and circulating tumor cells (CTCs) analysis. Targeted at cancer research institutions and clinical researchers across Spain.
- Experimental Models Working Module A module promoting collaborative research by sharing resources, expertise and experimental material (in vitro and in vivo models) including PDO, 3D Cultures, Primary Cultures, Micro-environment models, PDX, Hu-PDX, Xenograft, and GEMM, available at CIBERONC groups to fight cancer.
- Immuno-Oncology Working Module A module focused on immuno-oncology research including the IO Network, collaborative projects, and open calls for cancer immunotherapy research and response prediction.
- Bioinformatics Working Module A module providing bioinformatics support including CIBERONC cloud services on Microsoft Azure for data storage, virtual machines, and bioinformatics analysis tools to enable cross-institutional data sharing and analysis.
- SpadaHC Platform A technology platform offered by CIBERONC for biomedical research support within the consortium.
- CANCERTOOL A bioinformatics tool for visualization and representation of gene expression data in cancer research, used by researchers within the consortium.
- PANIPAC Research Project A collaborative therapeutic research project developing a nanoparticule-based approach (photoactivable nanoparticles) for pancreatic cancer treatment.
- METASTARG Research Project A collaborative nanomedicine research project aimed at combating cancer metastasis through novel therapeutic approaches.
- CloneSight Diagnostic Test A Spanish minimal residual disease (MRD) test showing promise in predicting late relapse in early breast cancer, developed through collaboration with Instituto Valenciano de Oncología.
Companies that use CIBERONC
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
CIBERONC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature5 records
CIBERONC partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and flagship.
- CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas)coreHost institution for CIBERONC Liquid Biopsy Workshop focusing on multimodal liquid biopsy techniques and new analysis strategies for localized tumors research. Venue for technical training and collaborative workshops.
- ISLB (International Society of Liquid Biopsy)flagshipISLB 2023 - 5th Annual Liquid Biopsy Congress held in Madrid. First international professional organization committed to liquid biopsy implementation in clinical practice, founded in 2017. CIBERONC actively participates in organizing and hosting these international events.
- ASEICA (Asociación Española de Investigación sobre el Cáncer)flagshipSpanish Cancer Research Association. CIBERONC collaborates on the ASEICA International Congress, an annual meeting that brings together cancer researchers including scientific coordination by Dr. Luis Paz-Ares, Dr. Marisol Soengas, Dr. Verónica Torrano, Dr. Miguel Sanmamed, and Dr. Rafael López.
- CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras)coreCollaborative partner in the V Young Researchers Meeting, connecting early and senior career researchers across CIBERONC (cancer) and CIBERER (rare diseases) to establish scientific discussion and networking between research groups.
- Gordon Research Conference (Liquid Biopsy for Cancer)coreInternational scientific conference series on Liquid Biopsy for Cancer. CIBERONC participates in and supports these conferences which bring together global experts in circulating tumor cells and liquid biopsy technologies.
- Instituto Valenciano de OncologíacoreCollaborative research partner in liquid biopsy studies, including the CloneSight MRD test development for early breast cancer recurrence prediction. The partnership brings together clinical and research expertise for circulating biomarker validation.
- International Society of Liquid Biopsy (ISLB)flagshipInternational professional organization dedicated to improving and implementing liquid biopsies in clinical practice. CIBERONC participates in ISLB annual congresses and contributes to the organization's education and information programs for advanced cancer research.
- Consorci Mar Parc de Salut BarcelonacoreMember institution of the CIBERONC Liquid Biopsy Ecosystem, contributing to circulating biomarker research and serving as a Barcelona-based research site for cancer liquid biopsy studies.
- Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)coreMadrid-based research institution member of the CIBERONC ecosystem, contributing to liquid biopsy research infrastructure and serving as a regional research hub.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
CIBERONC competitors and assessment
Company assessmentDirect peers
- EORTC (European Organisation for Research and Treatment of Cancer): Europe-based non-profit cancer clinical-research infrastructure running multi-center clinical trials across European institutions. Closely comparable to CIBERONC in mission (collaborative, multi-institutional cancer research) though more clinically trial-focused.
- CIBERES (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias): CIBER thematic area for respiratory diseases. Operates under the same consortium model as CIBERONC, providing a structural peer for benchmarking governance and program delivery.
- CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas): Another CIBER thematic area covering diabetes and metabolic diseases. Shares the exact consortium structure, governance model, and funding mechanism as CIBERONC, making it a direct operational peer.
- CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras): Sister thematic area within the same CIBER consortium, focused on rare diseases. Operates under an identical ISCIII-funded consortium model with shared working-module infrastructure, making it the closest operational peer to CIBERONC.
- CIBERSAM (Centro de Investigación Biomédica en Red de Salud Mental): CIBER thematic area for mental health research. Shares CIBERONC's consortium structure, ISCIII funding pathway, and working-module approach, providing a direct operational peer.
Broad incumbents
- Cancer Research UK: The world's largest independent cancer-research charity, funding research across UK institutions. Comparable to CIBERONC in coordinating national-scale cancer research through funded partnerships, but operates as a charity rather than a public consortium.
- National Cancer Institute (NCI): The US federal government's principal agency for cancer research and training. Comparable in mandate (national-scale cancer research coordination) though far larger in scale and budget.
- CIBER (Centro de Investigación Biomédica en Red): Parent consortium that hosts CIBERONC and other thematic areas. Provides shared governance, institutional legitimacy, and the funding envelope that defines CIBERONC's operating model.
- International Agency for Research on Cancer (IARC / WHO): WHO's specialized cancer research agency coordinating international cancer research. Operates at a global scale comparable to CIBERONC's mandate but with international rather than national scope.
Others
- American Association for Cancer Research (AACR): Major professional society for cancer researchers globally. Adjacent to CIBERONC in that it convenes and supports cancer researchers through conferences and publications, but is a membership society rather than a research consortium.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CIBERONC social profiles
Digital presenceCIBERONC compliance and trust
Trust signalCompliance1 record
CIBERONC financial estimates
Financial estimateRevenue estimate
Valuation estimate
CIBERONC leadership team
Management profileNumber of profiles
Profiles1 record
CIBERONC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CIBERONC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CIBERONC
What does CIBERONC do?
CIBERONC (Centro de Investigación Biomédica en Red Cáncer) is a publicly funded Spanish biomedical research consortium that coordinates collaborative cancer research across member institutions. It operates four interconnected Working Modules — Liquid Biopsy, Experimental Models, Immuno-Oncology, and Bioinformatics — providing shared experimental models, standardized protocols, cloud-based bioinformatics infrastructure, and competitive project funding to advance cancer diagnosis, treatment, and precision oncology.
Is CIBERONC a public or private company?
CIBERONC is a private company. It is classified as state government owned and is currently operating.
When was CIBERONC founded?
CIBERONC was founded in 2007. It employs 11 to 50 people.
Where is CIBERONC based?
CIBERONC is headquartered in Madrid, Spain, in the Europe region.
How does CIBERONC make money?
One revenue line is on record: public Research Funding.
Who are CIBERONC's main competitors?
Direct peers on record are EORTC (European Organisation for Research and Treatment of Cancer), CIBERES (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas), CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras) and CIBERSAM (Centro de Investigación Biomédica en Red de Salud Mental). Broad incumbents are Cancer Research UK, National Cancer Institute (NCI), CIBER (Centro de Investigación Biomédica en Red) and International Agency for Research on Cancer (IARC / WHO). American Association for Cancer Research (AACR) is listed as an others.
Does CIBERONC have an API?
No public API is recorded for CIBERONC.